NCCN 2nd Annual Congress: Hematologic Malignancies – Tumor Lysis Syndrome
Download Podcast
Listen to MP3
Podcast Evaluation
A presentation from the NCCN 2nd Annual Congress: Hematologic Malignancies™ held September 14-15, 2007, in New York, New York
Presenter
David J. Straus, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Faculty Disclosure Statement
Dr. Straus has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has served as an advisor for Amgen Inc.; Eisai Inc.; Therakos, Inc.; and Watson Pharmaceuticals, Inc. He has also served as a researcher for Ortho Biotech Products, L.P.
Dr. Straus has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Program Overview
Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of new advances. In addition, targeted therapies and oral treatments bring new benefits to patients. This presentation will focus on the management of tumor lysis syndrome in patients with hematologic malignancies.
Educational Objectives
Following this activity, participants should be able to:
- Describe the signs and symptoms of tumor lysis syndrome
- Summarize the management of tumor lysis syndrome
Intended Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.
Activity Instructions
Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than November 1, 2008. There is no fee for participating in this activity.
Download Podcast
Listen to MP3
Podcast Evaluation
Accreditation Information
Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
NCCN designates this educational activity for a maximum of 0.5 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
This activity is approved for 0.5 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
Release date: November 1, 2007
Expiration date: November 1, 2008
|